Tigecycline #88058

Tigecycline, also known as GAR-936, is a broad spectrum glycylcycline antimicrobial that binds to the bacterial 30S ribosome, blocking the entry of transfer RNA. This prevents protein synthesis and limits bacterial growth. Tigecycline has a 9-t-butyl-glycylamido side chain on the central skeleton, giving it the ability to overcome most tetracycline resistance mechanisms (1). In vitro studies have shown that Tigecycline has activity against multidrug-resistant Gram-negative and -positive bacteria, vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis (MRSE), and penicillin-resistant Streptococcus (1,2). Studies have also found that Tigecycline can selectively kill human leukemia stem and progenitor cells with no disruption to normal hematopoietic cells (3). This small compound has been shown to induce apoptosis and inhibit cell proliferation in cervical cancers by suppressing the Wnt/β-catenin signaling pathway (4).